Prospective Analysis of the Treatment of Progressive Familial Intrahepatic Cholestasis (TreatFIC)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity Medical Center Groningen

About this trial

The project has the following general aims:

1. Natural course and prognosis: To prospectively follow the natural course and prognosis of the different types of PFIC, to broaden the understanding of the different very rare diseases and to allow predictions about the course of disease in different types of PFIC. 2. Efficacy: To define the course of disease in FIC patients and identify associations with different treatments (symptomatic treatments, interruption of the enterohepatic circulation by surgical or medical means and other therapies such as corrector/potentiator or exon skipping therapy. The course of disease will be characterized by biochemical, clinical and surgical parameters, including liver transplantation. 3. Safety: To define the complications associated with the different treatments (symptomatic treatments, interruption of the enterohepatic circulation by surgical or medical means and other therapies such as corrector/potentiator or exon skipping therapy, liver transplantation). Follow up will be as long as possible. 4. (Surrogate) biomarker response: Biochemical parameters will be longitudinally collected and associated with changes in treatments / course of disease. 5. Genotype-phenotype relationships: If patient numbers permit, to establish genotype-phenotype relationships for (non)responsiveness towards different treatments in patients with genetic mutations causing the different forms of FIC disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

The diagnosis of a PFIC type disease needs to be performed according to the international guidelines, based on (episodes with a) low gamma-GT cholestasis and identification of disease-causing mutations in the indicated genes.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • observational study

    Other intervention

    The interventions are not determined by the study, which is purely observational on "real world data".

Treatment groups

200 Participants
are divided into 4 treatment groups
Group A: FIC1-deficiency1 intervention
Group B: BSEP-deficiency1 intervention
Group C: MDR3-deficiency1 intervention
Group D: Other genetic subtypes of Familiai Intrahepatic Cholestasis0 interventions

Trial outcomes

Primary outcomes

1

Number of participants with liver transplantation

The number (percentage) of patients undergoing liver transplantation related to the age of the patient

Time frame
at 5, 10, 15 and 18 years of age, as well as >18 years of age

Secondary outcomes

1

Number of participants that succumbed

Mortality related to age of the patient

Time frame
at 5, 10, 15 and 18 years of age, as well as >18 years of age

Other outcomes

1

Number of participant undergoing a surgical biliary diversion

Number of participant undergoing a surgical biliary diversion related to age

Time frame
at 5, 10, 15 and 18 years of age, as well as >18 years of age

Sponsors and contacts

Click on the lead sponsor to view all of their trials.